FDA Approves Additional Doses of Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes
INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved two additional doses of Eli Lilly and Company ' s (NYSE: LLY) Trulicity® (dulaglutide). The approval expands the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Food and Drug Administration (FDA)